Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis()

This systematic review and meta-analysis evaluated anti–programmed cell death (PD)-1 immunotherapy (nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy or other conventional drugs in the treatment of malignant tumors. We searched the followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ran, Peng, Pei-Chun, Wen, Bin, Li, Fu-Ying, Xie, Sheng, Chen, Guozhong, Lu, Jiefu, Peng, Zhuoyu, Tang, Shao-Bo, Liang, Yu-Mei, Deng, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800062/
https://www.ncbi.nlm.nih.gov/pubmed/26947879
http://dx.doi.org/10.1016/j.tranon.2015.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800062/
https://www.ncbi.nlm.nih.gov/pubmed/26947879
http://dx.doi.org/10.1016/j.tranon.2015.11.010

Ejemplares similares